As a result, they can help people control type 2 diabetes and lose weight
Neuroimage 181 , 279291 (2018)
Safety and Clinical Management Safety trials of GLP-1 RAs, including liraglutide, tirzepatide, and semaglutide (oral or subcutaneous), indicate that the most common adverse events (AEs) of treatment are mild to moderate gastrointestinal including nausea, vomiting, diarrhea, constipation, dyspepsia, and decreased appetite
Kunal Shah, an assistant professor in the division of endocrinology at the Rutgers Robert Wood Johnson Medical Center in New Brunswick, New Jersey
10.1530/joe-19-0451 [DOI] [PubMed] [Google Scholar] Tolessa, T
8df) in the muscle of mice supplemented with VD+LC compared with VD alone